Anticoagulant Reversal in Intracerebral Hemorrhage

In a patient with CT-confirmed ICH and current or suspected anticoagulant exposure, immediately establish the drug, dose, time of last administration, renal status, indication for anticoagulation, and whether emergency hematoma evacuation or another invasive procedure may be needed. Up to half of patients with oral-anticoagulant-associated ICH experience early clinical deterioration related to active bleeding and hematoma enlargement; rapid reversal is intended to limit expansion and facilitate surgery when necessary. ScienceDirect+2ScienceDirectAnticoagulant-associated intracerebral hemorrhageScienceDirectAnticoagulant-associated intracerebral hemorrhage - ScienceDirectPubMedRace against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage - PubMed

Run reversal and acute ICH management in parallel: obtain CBC, PT/INR, aPTT, creatinine, type and screen, and agent-specific testing if locally available, while activating neurology/neurocritical care and neurosurgical pathways. The 2022 AHA/ASA ICH guidance emphasizes early anticoagulant reversal and early systolic blood-pressure reduction, and AHA/ASA performance measures identify a 90-minute anticoagulation-reversal target. AHA Journals+1AHA JournalsTime to Acute Treatment in Intracerebral Hemorrhage Lags ...WileyConsensus Recommendations for Clinical Pharmacist Integration ...

Do not use a normal conventional coagulation assay to exclude clinically meaningful direct oral anticoagulant activity. Agent-specific anti-Xa assays detect rivaroxaban or apixaban activity, whereas thrombin time, dilute thrombin time, ecarin clotting time, and ecarin chromogenic assay detect dabigatran; however, calibrated assays may be unavailable or delayed. BMJBMJLaboratory measures of coagulation among trauma patients on NOAs: results of the AAST-MIT | Trauma Surgery & Acute Care Open

For warfarin-associated ICH, administer intravenous vitamin K and PCC promptly. Vitamin K plus PCC is the established reversal strategy for VKA-associated ICH, whereas PCC supplies vitamin K-dependent clotting factors for rapid correction and vitamin K addresses sustained warfarin effect. BMJ+1BMJAnticoagulation associated intracerebral haemorrhage trends ...AHA JournalsAnticoagulant-Associated Intracranial Hemorrhage in the ...

Obtain PT/INR before treatment when this does not delay therapy, then repeat INR after reversal to identify incomplete correction or recurrent anticoagulant effect. The urgent clinical objective is correction of VKA-associated coagulopathy during the period of greatest risk for hematoma expansion rather than waiting for spontaneous INR decline. AHA Journals+2AHA JournalsAnticoagulant-Associated Intracranial Hemorrhage in the ...ScienceDirectAnticoagulant-associated intracerebral hemorrhageScienceDirectAnticoagulant-associated intracerebral hemorrhage - ScienceDirect

Avoid substituting unstructured plasma-only strategies when PCC is available for urgent VKA reversal. FFP has been used historically in anticoagulant-associated intracranial hemorrhage, but contemporary descriptions identify vitamin K and PCC as the reversal cornerstones. AHA Journals+1AHA JournalsAnticoagulant-Associated Intracranial Hemorrhage in the ...PubMedRace against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage - PubMed

For dabigatran-associated ICH, use idarucizumab as the specific reversal agent. If exposure is uncertain or the timing of the last dose is unclear, a thrombin time, dilute thrombin time, or ecarin-based assay can detect dabigatran activity, but limited availability and turnaround commonly constrain their use in the emergency setting. BMJ+1BMJLaboratory measures of coagulation among trauma patients on NOAs: results of the AAST-MIT | Trauma Surgery & Acute Care OpenBMJAntiplatelets and antithrombotics in neurointerventional procedures

For apixaban- or rivaroxaban-associated ICH requiring reversal, andexanet alfa is a specific factor Xa inhibitor reversal agent approved by the FDA in 2018. It is a modified recombinant inactive factor Xa that binds and sequesters factor Xa inhibitors. Select low- versus high-dose administration according to the patient’s anticoagulant dose and time since last ingestion. BMJBMJAntiplatelets and antithrombotics in neurointerventional procedures

The andexanet regimen is either a 400-mg or 800-mg intravenous bolus at 30 mg/min followed by 4 mg/min or 8 mg/min, respectively, for up to 120 minutes. When andexanet alfa is unavailable, 4-factor PCC 2,000 units is a recommended alternative for apixaban or rivaroxaban reversal in the cited guidance. BMJBMJAntiplatelets and antithrombotics in neurointerventional procedures

For edoxaban or betrixaban, the cited guidance describes off-label andexanet alfa at an 800-mg bolus followed by 8 mg/min for up to 120 minutes, or 4-factor PCC 2,000 units. Make the off-label status explicit in the treatment record and involve pharmacy early when the exposure is not apixaban or rivaroxaban. BMJBMJAntiplatelets and antithrombotics in neurointerventional procedures

For ICH during an unfractionated heparin infusion, stop the infusion and administer intravenous protamine sulfate at 1 mg per 100 units of heparin received during the preceding 2-3 hours, to a maximum of 50 mg. Repeat aPTT after treatment; if aPTT remains elevated, repeat protamine at one-half of the initial dose. BMJBMJCurrent management of spontaneous intracerebral haemorrhage | Stroke and Vascular Neurology

For subcutaneous prophylactic unfractionated heparin, do not routinely reverse solely because ICH is present. Consider protamine only when aPTT is significantly prolonged in the setting of new hemorrhage, because therapeutic rather than prophylactic anticoagulant effect is the actionable target. BMJBMJCurrent management of spontaneous intracerebral haemorrhage | Stroke and Vascular Neurology

For therapeutic-dose enoxaparin, give protamine 1 mg per 1 mg enoxaparin when the last dose was within 8 hours, or 0.5 mg per 1 mg when it was 8-12 hours earlier. For dalteparin, nadroparin, or tinzaparin, use 1 mg protamine per 100 anti-Xa units, with a maximum dose of 50 mg. BMJBMJCurrent management of spontaneous intracerebral haemorrhage | Stroke and Vascular Neurology

LMWH reversal with protamine is partial. If bleeding continues or renal insufficiency raises concern for persistent LMWH effect, the cited regimen permits a repeat dose equal to one-half the initial protamine dose; recombinant factor VIIa is generally not recommended and is considered only if protamine is contraindicated. BMJ+1BMJCurrent management of spontaneous intracerebral haemorrhage | Stroke and Vascular NeurologyBMJAntiplatelets and antithrombotics in neurointerventional procedures

After reversal, monitor neurologic status, blood pressure, and imaging for evidence of hematoma enlargement. Hematoma expansion and early neurologic decline remain central threats in oral-anticoagulant-associated ICH; rapid coagulopathy correction and blood-pressure control are the principal acute medical measures directed at these risks. ScienceDirect+1ScienceDirectAnticoagulant-associated intracerebral hemorrhageScienceDirectAnticoagulant-associated intracerebral hemorrhage - ScienceDirect

Escalate early to neurosurgery when the clinical or radiographic course raises concern for hematoma evacuation or another urgent intracranial procedure. Anticoagulant correction is particularly important when surgery is being considered because it may facilitate operative intervention and reduce continued bleeding risk. PubMedPubMedRace against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage - PubMed

Do not set a routine anticoagulation-restart date at the time of emergency reversal. Restart should be individualized after hematoma stability, hemorrhage mechanism, thromboembolic indication, and rebleeding risk have been reassessed. A cited consensus framework supports resuming anticoagulation once thrombotic risk exceeds rebleeding risk; in some non-neurovascular major-bleeding scenarios this can occur within 1 week, but neurointerventional data are less clear. BMJBMJAntiplatelets and antithrombotics in neurointerventional procedures